<DOC>
	<DOCNO>NCT02262780</DOCNO>
	<brief_summary>Group 1 : To investigate safety , tolerability pharmacokinetics Telmisartan + HCTZ ( T40/H12.5 T80/H12.5 ) Group 2 : To investigate safety , tolerability pharmacokinetics Telmisartan + HCTZ ( T80/H12.5 x 7 day )</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Multiple Oral Doses Telmisartan / Hydrochlorothiazide ( HCTZ ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Healthy male accord follow criterion : No find deviate clinical relevance evidence clinically relevant concomitant disease base upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) , body temperature ) , 12lead ECG , clinical laboratory test Age ≥20 Age ≤35 year Body Mass Index ( BMI ) ≥17.6 BMI ≤26.4 kg/m2 Signed date write informed consent prior admission study accordance `` Good Clinical Practice ( GCP ) '' Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection Any laboratory value outside reference range clinical relevance Positive result hepatitis B surface ( HBs ) antigen , anti hepatitis C virus ( HCV ) antibody , Syphilitic test HIV test Surgery gastrointestinal tract ( except appendectomy ) History relevant orthostatic hypotension ( mean stand SBP varies ≥ 20 mmHg mean supine systolic blood pressure ( SBP ) and/or mean stand diastolic blood pressure ( DBP ) vary ≥ 10 mmHg mean supine DBP ) , faint spell blackout . History hepatic dysfunction ( e.g . biliary cirrhosis , cholestasis ) History serious renal dysfunction History bilateral renal artery stenosis renal artery stenosis solitary kidney History cerebrovascular disorder History hyperkalemia Known hypersensitivity component formulation ; know hypersensitivity angiotensin II receptor antagonist ; know hypersensitivity sulfonamide sulphonamidederived drug ( e.g . thiazide ) History impair glucose tolerance History hypokalemia History hyperuricemia Salt restriction therapy Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 7 day prior administration trial Participation another trial investigational drug within four month 6 halflives investigational drug , whichever longer , prior administration trial Smoker ( 20 cigarette /day ) Alcohol abuse Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within seven day prior administration ) Intake alcohol within two day prior administration Inability comply dietary regimen study centre Inability comply smoke cessation hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>